Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upRichard A. Larson, H. Kantarjian, Andreas Hochhaus et al.|Leukemia|2012Cited by 440
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid LeukemiaClaude Preudhomme, François Guilhot, Joëlle Guilhot et al.|New England Journal of Medicine|2010Cited by 385
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaMatthew S. Zabriskie, Thomas O’Hare, Marina Konopleva et al.|Cancer Cell|2014Cited by 366
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLLIan W. Flinn, Stephan Stilgenbauer, Peter Hillmen et al.|Blood|2018Cited by 341